Welcome to Plenary Session.

I'm Vinay Prasad. I'm an associate professor with University of California, San Francisco.

I'm a practicing he-mong doctor, and my interests are medicine, oncology, and health policy.

And that's what you're going to get on Plenary Session.

This is season four, hashtag zero COVID.

It's zero COVID because we're not going to talk about COVID.

We're back, oncology, medicine, health policy.

We've got a lot in store for you.

But first, a plug.

If you like this podcast, leave us a rating or write us a review. It helps new listeners find the show. You can follow us on Twitter at Plenary underscore Session. You can email us at plenary session podcast at gmail.com. Give us your suggestions on what we should be covering. And we got a new YouTube channel, Vinay Prasad, MDMPH. Follow us on YouTube. I'm putting up a 10-part series on reading and interpreting cancer clinical trials.

You'll want to watch it there.

And if you really love this show, you can back us on patreon.com.

Patreon backers get access to slides for lectures I give on Plenary Session.

And with that, let's start the show.

I think we're rolling. I think we're rolling.

I'm back, plenary session, video edition, joined by Amit Sarpatwari. Professor Sarpatwari is an assistant professor at the Harvard Medical School. He's in the portal group, the program on

regulation, therapeutics, and law. And he is an expert in epidemiology and legal affairs, in regulatory science. And he is friend of the show amit it's great to have you back here again it's great to be here um good to see you uh somewhat face to face to face as face to face as it's gotten in a long time exactly well there's so much to talk about you know the fda just keeps hitting the ball out of the park, making sure innovation happens in this country. But before we get to all the fun of aducanamab or aducanamab or whatever the hell you want to call it, let's talk a little bit about the exodus. And I'm talking about the exodus from the Academy, Dr. Sarpatwari, the Academy.

So in the last few weeks, we've seen some people who I think are quite good. And I'll be honest to say, I think they are sharp.

You know, people will know. I've, of course, you know, I've had my disagreements with Peter Bach over the years, but I've had a lot of agreements with Peter Bach over the years. But one thing I will con of course, you know, I've, I've had my disagreements with Peter Bach over the years,

but I've had a lot of agreements with Peter Bach over the years.

But one thing I will concede is that Peter Bach is a clever person.

And sometimes I read his papers often.

...